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Background: Previously, we showed that the tetraspanin membrane protein CD63 mediates both early and post-
integration stages of the HIV-1 replication cycle. The temporal roles of CD63 were discerned using monoclonal
antibodies and small interfering RNAs (siRNAs) to block CD63 function, and determining which of the sequential
steps in HIV-1 replication were disrupted. Inhibition was shown to occur during early infection, suggestive of
involvement in virus entry or reverse transcription. In addition, we have shown that treatment with CD63 siRNA
post-infection, significantly inhibited virus production in supernatant, suggesting an important role for CD63 in
macrophages during HIV-1 replication events occurring after proviral integration, and possibly during egress.
Results: In this study we used CD63 siRNA to investigate the infectivity of pseudotyped viruses (carrying an NL4-3
Env-negative luciferase backbone) in primary human macrophages. We demonstrated that lab adapted R5- and
R5X4-tropic HIV-1 strains are significantly inhibited by CD63 silencing. However, the infectivity of MLV or
VSV-pseudotyped strains, which enter though receptor-mediated endocytosis, is unaffected by silencing CD63.
These results indicate that CD63 may support Env-mediated entry or fusion events facilitated though CD4 and
CCR5. Also, antibody and siRNA-based CD63 inhibition studies indicate a potential role for CD63 following
proviral integration. Further, we show that CD63 expression is key for efficient replication in primary CD4+ T cells,
complementing our prior studies with primary human macrophages and immortalized cell lines.
Conclusions: Collectively, these findings indicate that CD63 may support Env-mediated fusion as well as a late
(post-integration) step in the HIV-1 replication cycle.
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Macrophages (MØ) and CD4+ T lymphocytes are target
reservoirs for HIV-1 infection and replication, and play
critical roles in multiple aspects of viral pathogenesis.
HIV-1 relies on numerous host determinants for suc-
cessful completion of each of the replicative steps of the
viral life cycle from entry to egress [1-11].
CD63 is a type II cellular membrane protein belonging
to the tetraspanin superfamily [12,13]. CD63 associates
with tetraspanin-enriched microdomains (TEMs), which
have been shown to act as gateways for HIV-1 budding* Correspondence: mrfergus@utmb.edu
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stated.at the plasma membrane [14]. Numerous studies have
shown that CD63 readily incorporates into HIV-1 virions
[15-17] and partially colocalizes with HIV-1 Env and
Gag proteins in HIV-1 producing cells [16,18-21]. Colo-
calization and virion incorporation data indirectly sug-
gest a positive role for CD63 in the HIV-1 replication
cycle, although this has not always been borne out ex-
perimentally, and conflicting results have been observed.
For example, a recent study showed that CD63 suppresses
trafficking of the chemokine receptor CXCR4 to the cell
surface, which affects HIV-1 entry into T lymphocytes
[22-24]. However, we have demonstrated that anti-CD63
monoclonal antibody or siRNA treatment does not affect
the expression of the other major coreceptor CCR5, or the
primary receptor CD4 [25-27]. Another recent paper
showed CD63 is not required for HIV-1 infection of
human MØ [28], in contrast with our prior studies.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
































Figure 1 CD63 facilitates HIV-1 env-mediated entry in human
MØs. Human monocyte derived MØ (5 × 105 cells/well) were
transfected with 50 nM siRNAs (CD63, CD4, and ERBB2IP). Forty-eight
hours post-transfection, cells were transduced with reporter viruses
pseudotyped with various viral Env proteins (m.o.i. = 0.02) that
contained the HIV-1 NL4-3 envelope-negative luciferase backbone.
Cell lysates were collected on day 3 post-transduction, and luciferase
activities were analyzed to monitor pseudovirus integration. MLV and
VSV were used as controls for the entry step because they enter the
cells via receptor-mediated endocytosis. In contrast, pseudoyped viruses
coated with R5 (ADA) and R5/X4 dual-tropic (89.6) HIV-1 Env proteins
gain entrance into MØs by sequential Env interactions with CD4 and
CCR5, resulting in viral-cell membrane fusion. All experiments were
performed in quadruplicate. *P < 0.05, compared with ERBB2IP group.
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is important for HIV-1 replication in primary MØ and CD4
+ cell lines [25-27,29]. Our earlier studies showed that anti-
CD63 monoclonal antibody treatment 30 min prior to and
during infection markedly reduced HIV-1 replication in
MØ [25]. Inhibition was shown to occur during early infec-
tion, suggestive of involvement in virus entry or reverse
transcription. Subsequently, we confirmed the requirement
of CD63 in HIV-1 replication in primary human MØ and
an immortalized CD4+ cell line following CD63 down regu-
lation by siRNA [26,27], and presently show its requirement
by HIV-1 in primary human CD4+ T lymphocytes. Here,
we show that CD63 expression supports Env-mediated fu-
sion during MØ transduction with pseudotyped viruses.
Down modulating CD63 expression in latently infected U1
cells blocked viral egress, but not intracellular p24 produc-
tion, indicating CD63 also regulates a late replication step
(s). Implications of our findings with regard to me-
chanisms of HIV-1 replication are discussed below.
Results and discussion
CD63 facilitates virus Env-mediated entry in human MØ
We studied the effect of silencing CD63 expression on the
transduction of various pseudotyped viruses carrying an
NL4-3 envelope-negative luciferase backbone. Primary hu-
man MØ were transfected with siRNAs (CD63, CD4, or
ERBB2IP). The efficiency of CD63-specific siRNA down
regulation has been shown in our previous studies [26,27].
Forty-eight hours post-transfection, cells were transduced
with various Env-specific reporter pseudoviruses (MLV,
VSV, HIV-1ADA, or HIV-189.6) for single-cycle infection.
Luciferase activities were analyzed 3 days post-infection to
monitor pseudovirus integration. MLV and VSV (carrying
the same NL4-3 envelope-negative luciferase backbone)
were used as controls because they enter the cell via endo-
cytosis, independently of CD4 and chemokine receptor
usage. ERBB2IP siRNA was used as a cellular target nega-
tive control, as our previous studies showed that silencing
ERBB2IP does not inhibit HIV-1 [30,31]. Figure 1 shows
that when viral entry is mediated though CD4 and corecep-
tor CCR5 using R5 (HIV-1ADA) or dual-tropic (HIV-189.6)
pseudotyped envelopes, infectivity is significantly reduced
in CD63-silenced MØ; consistent with the CD4 siRNA
control. However, when viral entry is redirected though
the endocytic pathway by pseudotyping virions with
MLV or VSV, infectivity is not affected in CD63- or
CD4-silenced MØ.
CD63 mRNA down regulation by siRNA in human
peripheral blood lymphocytes (PBLs)
Like human MØ, CD4+ T lymphocytes are also target
reservoirs for HIV-1 infection and replication. In our
previous studies we showed that CD63 silencing affects
HIV-1 production in monocyte-derived MØ and a CD4+cell line [25-27], and we now extend our investigations
to study the role of CD63 in primary human peripheral
blood lymphocytes (PBLs).
Efficient silencing of CD63 mRNA expression in PBLs
with siRNA was confirmed by quantitative reverse tran-
scriptase PCR (qRT-PCR). CD63 mRNA expression was
reduced by >92% following CD63 siRNA transfections of
PBLs (Figure 2A). CD63 mRNA was not significantly re-
duced by control siRNA transfections (CD4, ERBB2IP)
indicating specificity for CD63 siRNA down regulation
in PBLs. Western blot analysis revealed that CD63 pro-
tein expression (53 kDa) was significantly reduced in
CD63-siRNA transfectants compared to untransfected
cells (Figure 2B). Reducing CD63 expression in PBLs did
not affect viability, as assayed by coupling GAPDH to
3-phosphoglyceric phosphokinase and measuring ATP
production (data not shown).
CD63 down regulation affects HIV-1 production in
human PBLs
We sought to elucidate the effect of CD63 down regula-
tion on viral production in PBLs. PBLs were transfected
with CD63 siRNA or control siRNAs (ERBB2IP or CD4)
for 48 h, followed by infection with HIV-189.6. HIV-1
production was assessed in culture supernatants by p24
ELISA at 7 days post-infection. As shown in Figure 2C,
virus production in PBLs was significantly reduced fol-
lowing CD63 or CD4 silencing compared to ERBB2IP
siRNA transfected cells (P < 0.05). Thus, our data strongly






Figure 2 Silencing CD63 expression in human PBLs by RNA interference and its effect on HIV-1 replication. (A) PBLs (1 × 105 cells/well)
were plated in triplicate in 24-well plates and transfected with 50 nM siRNAs (CD63, CD4, and ERBB2IP). Controls included untreated cells. Total
mRNA was isolated from each well using the Qiagen RNeasy kit 48 h after transfection. Quantitative RT-PCR was used to determine relative CD63
expression levels, normalizing to GAPDH expression as an internal control. CD63 expression in non-transfected cells was set to 100%. (B) Western
blot analysis was performed using cell lysates obtained from PBLs 48 h after transfection. The blot was probed with anti- human CD63 antibody,
or an anti-β-actin antibody as an internal control for cellular protein expression. The upper panels of lanes 1 and 2 show the respective expression
of CD63 in untreated cells and in CD63 siRNA transfectants. (C) PBLs (1 × 105 cells/well) were plated in triplicate in 24-well plates and transfected
with 50 nM siRNAs (CD63, CD4, and ERBB2IP). Forty-eight hours post-transfection, cells were infected with HIV-189.6 (m.o.i. = 0.02). Supernatants
obtained from PBLs were harvested for p24 detection on day 7 post-infection using p24 Capture ELISA kit (ImmunoDiagnostics, Woburn, MA).
*P < 0.05, **P < 0.01, compared with ERBB2IP control group, respectively.
Li et al. Virology Journal 2014, 11:23 Page 3 of 7
http://www.virologyj.com/content/11/1/23CD63 down regulation also affects later events of the
HIV-1 replication cycle
To further assess the role of CD63 in late stage HIV-1
replication, CD63 siRNA was transfected into U1/HIV-1
cells, which are chronically infected monocytoid cells
harboring 2 integrated copies of provirus per cell
[32,33]. Early steps of HIV-1 replication (such as entry
and reverse transcription) are not required for replica-
tion in these cells, and virus production can be induced
with 3 phorbol 12-myristate 13-acetate (PMA). Silencing
CD63 did not significantly inhibit intracellular p24 pro-
duction (Figure 3A), suggesting that CD63 does not
regulate viral p24 protein production. However, extracel-
lular HIV-1 p24 obtained from supernatants was signifi-
cantly reduced in CD63- and TSG101-depleted U1 cells
(p < 0.05) compared to the ERBB2IP siRNA control
(Figure 3B). TSG101 is involved in post-integration traf-
ficking and release of HIV-1 Gag proteins [34]. Similar
to TSG101, these findings indicate that CD63 may also
serve a role in the release of HIV-1 from the cell, which
may relate to why HIV-1 readily incorporates CD63 intonascent virions. These outcomes are also consistent with
our previous studies performed in primary MØ. Treat-
ment with CD63-specific siRNA 3 days post-infection,
significantly inhibited virus production in culture super-
natants [26], suggesting an important role for CD63 in
MØ during HIV-1 replication events occurring after
proviral integration, and possibly during egress.
Previously, we have shown that CD63 silencing signifi-
cantly inhibits HIV-1 replication in MØ [25,27], U1/
HIV-1 producing cells [26], U373 CD4+ cell line [26],
and presently in T lymphocytes (Figure 2C), revealing
that CD63 expression is broadly required for replication
in relevant HIV-1 target cells.
We further demonstrate dual roles for CD63, showing
that it contributes to both early and late events of the HIV-
1 replication cycle. CD63 mediated efficient entry of HIV-1
Env pseudotyped viruses into CCR5+ MØ (Figure 1). When
viral entry was redirected though the endocytic pathway by
pseudotyping virions with MLV or VSV, infectivity in MØ
was not affected by CD63 silencing. However, CD63 silen-
cing did reduce infectivity with R5- and R5X4-tropic viral
Figure 3 CD63 down regulation affects later events of the HIV-1 replication cycle. U1/HIV-1 cells (5 × 105 cells/well) were transfected with
CD63-, ERBB2IP-, CD4-, or TSG101-specific siRNA. Two days post-transfection, cells were induced with 3 phorbol 12-myristate 13-acetate (PMA, 5 ×
10-6 M). Three days post-induction, HIV-1 p24 protein in cell lysates (A) and culture supernatants (B) were detected using a p24 Capture ELISA kit
(ImmunoDiagnostics, Woburn, MA). TSG101-specific siRNA was used as a control because it is involved in post-integration trafficking, assembly,
and release of HIV-1 Gag proteins [34]. Experiments were performed in triplicate. *P < 0.05, compared to ERBB2IP group.
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indicates (i) that CD63 supports Env-mediated entry or fu-
sion events facilitated though CD4 and CCR5, and (ii) that
the entry events are specific for the HIV-1 Env protein. In
support, other investigators have demonstrated that the
extracellular domain 2 of CD63 partially colocalizes with
CD4 at the cell surface of macrophages [35].
CD63 also exerts a role in later stages of the HIV-1
replication cycle. As CD63 is a major component of late
endosomes, it is possible that CD63 is also involved in
HIV-1 maturation and budding in MØ. In this study, we
show that silencing CD63 expression decreases extra-
cellular, but not intracellular, HIV-1 p24 production
(Figure 3A, B), indicating that CD63 may influence viral
egress. In MØ, nascent HIV-1 virions accumulate and
assemble in multi-vesicular bodies (MVBs) or endo-
somes containing tetraspanins such as CD63 and CD81,
and may be released subsequently as exosomes. How-
ever, in T-cells HIV-1 Gag assembly is localized to the
plasma membrane [14] where CD63 is also found. As
CD63 is located in endosomes and the plasmamembrane where HIV assembly takes place, it is possibly
involved in virus assembly at these sites. This complex
localization pattern of CD63 suggests that its intracellu-
lar trafficking and distribution must be tightly regulated.
Several studies have shown that CD63 supports HIV-1
replication [25-27], is located at assembly initiation sites
[36-38], and is incorporated into nascent virions [15,16],
yet viral binding partners with CD63 have remained elu-
sive. Exactly how CD63 is targeted to viral assembly sites
and incorporated into budding HIV-1 particles also re-
mains unclear. A plausible explanation is that virus bud-
ding may occur in TEMs and that CD63 must be
present for the completion of the recycling loop with re-
turn of both CD63 and viral proteins to a common site
for virus release. CD63-containing TEMs may be required
for budding of virus from these cells.
Conclusions
In conclusion, we have shown that CD63 plays a role
both in the early entry stages of the HIV-1 replication
cycle in concert with CD4 and/or CCR5, and in a late
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research is needed to gain insight into the molecular
mechanisms of CD63 that facilitate early and late events
in the HIV-1 replication cycle.
Methods
Cells and culture conditions
Primary monocyte-derived macrophages (MØ) and periph-
eral blood lymphocytes (PBLs) were isolated and purified
from buffy coats of healthy HIV-negative blood donors
prepared by the UTMB Blood Bank (Galveston, TX).
Monocyte-derived MØ were prepared by Ficoll-Hypaque
gradient centrifugation followed by adherence for 7 days to
plastic petri dishes. During differentiation, MØ were cul-
tured in Iscove’s modified Dulbecco’s medium (IMDM)
[39] supplemented with 20% FCS; 1% L-glutamine and 1%
Penicillin/Streptomycin as described in [39]. Nonadherent
cells (PBLs) were treated with phytohemagglutinin (PHA)
for 72 h 37°C with 5% CO2 prior to propagation in RPMI
1640 supplemented with 20% fetal calf serum (FCS), 20
units/ml IL-2, 1% Penicillin/Streptomycin.
Our experimental research has been approved by the
Institutional Biosafety Committee (IBC) at the University
of Texas Medical Branch, Galveston, Texas. The IBC ref-
erence numbers are 2013040 (for use of HIV) and
2012033 (for use of primary cells and cell lines). There is
no use of animals or humans in our studies.
U1/HIV-1 cells [34] (1 × 106) obtained from the NIH
AIDS Research and Reference Reagent Program were
plated in 24-well microtiter plates on day 1. Complete
cell media (RPMI 1640 containing 2.0 mM L-glutamine;
10% heat-inactivated fetal bovine serum) was changed
after 24 h. Forty-eight hours post-transfection (day 3),
complete RPMI media plus phorbol 12-myristate 13-
acetate (PMA) was added to cells. Intracellular and
extracellular virus was measured in the cells lysates and
culture supernatant on day 5 by p24 ELISA.
Preparation of HIV-189.6
Dual-tropic (R5/X4) HIV-189.6 is an HIV-1 laboratory
adapted strain originally isolated from an infected indi-
vidual. The original preparation was prepared from mo-
lecularly cloned virus, and grown in CEMx174 cells [40]
and donated to the NIH AIDS Research and Reference
Reagent Program. We purchased HIV-189.6 from the Vir-
ology Core Facility, Center for AIDS Research at Baylor
College of Medicine, Houston, TX, which was prepared
and propagated in human PBMCs. HIV-189.6 stock con-
taining 49.977 ng/ml of HIV p24 with 261,300 TCID50/
ml was used to infect PBLs at an m.o.i of 0.02.
siRNA transfections and infectivity assay
siRNAs targeting CD63, CD4, ERBB2IP, and TSG101-
specific were designed and synthesized by Dharmacon(Lafayette, CO). The target sequences for siGENOME
SMARTpool siRNA of CD63 includes D-017256 (01-
GAGAUAAGGUGAUGUCAGA; 02-AAGGAGAACUA
UUGUCUUA; 03-GGAUUAAUUUCAACGAGAA; 04-
GAUGGAGAAUUACCCGAAA). The target sequences
for siGENOME SMARTpool siRNA of CD4 includes D-
005234 (01-GAACUGACCUGUACAGCUU; 02-AAUC
AGGGCUCCUUCUUAA; 03-GAAGAAGAGCAUACA
AUUC; 18-AUUACCAAGUGCCGGACUA); The target
sequences for siGENOME SMARTpool siRNA of
TSG101 includes M-003549 (01-AAACUGAGAUGGC
GGAUGA; 02-GAACCUCACUGGAACAAUC; 04-CC
GUUUAGAUCAAGAAGUA; 05-UCCCACAGCUCCC
UUAUAC). The target sequences for siGENOME SMART-
pool siRNA of ERBB2IP includes D-031861 (01-UGAAA
CAGCUCACAUAUUU; 02-UGUGAAAUCUCAUAGCA
UA; 03-CGAAGAGCCAAAUAUAAUA; 04-CCAAACGA
CCGACUUAUUC). siRNAs transfections were performed
using oligofectamine (Invitrogen, CA) or the Nucleofector™
Technology by Amaxa (Lonza, Switzerland) according to
the manufacturers’ instructions. In brief, MØ adherent for
5 days were plated in 24-well plates (5 × 105 cells/well),
and transfected with 50 nM siRNAs using oligofectamine
in serum-free Opti-MEM I medium (Gibco) 24 h after
plating. MØ were maintained in Iscove’s medium and 20%
FCS after 4 h to terminate transfection. U1/HIV-1 cells
were transfected with siRNA (200 nM final concentration)
using Oligofectamine (Invitrogen) following the manufac-
turer’s instructions.
In order to measure down regulation of target genes
in PBLs, cell lysates were prepared with cell lysis buffer
(Promega, WI) at 2 days post-transfection, and were col-
lected for Western blot analysis, or RNA was extracted
for real time quantitative PCR analysis. PBLs were trans-
fected with 50 nM siRNAs in 6-well plates (5 × 105 cells/
well) using Nucleofector®, and standard applications of
manufacture’s protocol (Amaxa) were followed. For
Western blot analysis, anti-human CD63 monoclonal
antibody (Santa Cruz) was used.
Forty eight hours post-transfection, PBLs were infected
with HIV-189.6 (m.o.i. = 0.02). Culture supernatants were
harvested for p24 detection on day 7 post-infection
using a p24 Capture ELISA kit (ImmunoDiagnostics,
Woburn, MA).
HIV-1 Env pseudovirus production and titration
Pseudotype viruses containing the luciferase gene pro-
vide an efficient way to measure infection after CD4,
CCR5, and CD63 down regulation. Stocks of single-
round-infection of various viral Env pseudoviruses (MLV,
VSV, HIV-1ADA, or HIV-189.6) were produced by cotrans-
fecting 293 T cells (1.7 × 107 cells per T75 flask) with 2 μg
of an HIV-1 rev/env expression plasmid and 12 μg of an
env-deficient HIV-1 backbone plasmid (pNL4.3 ΔEnv)
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The NL4-3 proviral clone has a luciferase in place of nef
(env-luc). Pseudovirus-containing supernatant was har-
vested 24 h following transfection and clarified by cen-
trifugation and 0.45-μm filtration. Single-use aliquots
(1.0 ml) were stored at −80°C. The 50% tissue culture in-
fectious dose (TCID50) for each pseudovirus preparation
was determined by infection of TZM-bl cells. These pseu-
dovirus stocks then were used for transduction of MØs.
Real time quantitative PCR
Total mRNA was isolated from siRNA-transfected cells
and MØ using RNeasy Mini Kits (Qiagen). CD63 spe-
cific primers and probe were purchased from Applied
Biosytems (Carlsbad, CA). All reactions were performed
using Applied Biosystems TaqMan Universal Master
Mix and run using an Applied Biosystems 7500 Fast Real
Time PCR system and 7500 Fast System Software. Silen-
cing of target genes was determined by normalizing tar-
get gene expression to GAPDH expression (n = 3).
Statistical analysis
The results are expressed as mean ± SD of at least four
wells. Two-tailed, paired Student’s t-test was used to de-
termine statistical significance. P values of <0.05*, and
<0.01** were considered significant.
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